Drug Discovery Today

AUGUST 5, 2021

(Oslo, August 5, 2021) Molecular diagnostics specialist, Genetic Analysis AS (GA) today announced the first publication from the comprehensive HumGut microbiome database has appeared in the leading scientific journal Microbiome. HumGut comprises a collection of about 30,000 genomes, covering the broad diversity of bacterial genomes found in the human gut.

Science 100

Science Research 100

Eye on FDA

AUGUST 4, 2021

As more drugs are being approved, is FDA getting less advice than in the past? FDA maintains a vast network of outside advisors to provide input and counsel to the agency related to decisions on policy as well as product approvals. There are 31 advisory committees on matters ranging from food to medical devices to pediatric care. Within those focused on human drugs , there are 17 committees organized under therapeutic categories (Arthritis, Cardiovascular and Renal, Gastrointestinal, e.g.).

FDA 122

FDA Clinical Pharmacology FDA Approval Therapies 122

Drug Patent Watch

AUGUST 6, 2021

This chart shows the pharmaceutical companies with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Bulgaria? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Drugs 98

Molecule Blog

AUGUST 6, 2021

Molecule’s Biopharma IP-NFTs — A Technical Description Summary Creating legal agreements between two parties for (pre-patent) biopharma assets is complicated, in-transparent and lengthy. Molecule is proposing a new kind of marketplace for early-stage biopharma IP through which stated IP can easily be bought, funded and collaborated on. This marketplace needs to enable transparent IP rights and legal agreement construction, meanwhile accounting for the sensitivity of early-stage IP.

Licensing 52

Licensing Licensing Marketing Research 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Discovery Today

AUGUST 3, 2021

New role for Dr Kath Mackay reflects ambitions of Bruntwood SciTech and growth of the UK’s life sciences sector

Science 113

Science 113

The Pharma Data

AUGUST 5, 2021

Researchers have created a new open-access database of information on drug candidates and how they are metabolised by the body, which could help speed up the repurposing of old drugs as new treatments. There is an urgent need for more effective treatments for many conditions, including COVID-19, cancer and malaria. But the process of developing new drugs is costly, can take decades, and often leads to failed treatments.

Disease 52

Disease Drugs Laboratories Engineering 52

Crown Bioscience

AUGUST 2, 2021

In this blog we will explore immune-mediated inflammatory diseases (IMIDs) —which represent a diverse group of conditions characterized by an excessive and/or inappropriate immune response. Interest in IMIDs has grown rapidly in recent years, largely fueled by the view that IMIDs share common inflammatory pathways, and therefore, there is the possibility that novel therapies that work in one IMID may work in other IMIDs.

Disease 52

Disease Drug Development Immune Response Drugs 52

Drug Channels

AUGUST 3, 2021

Looking for a summer beach read? I suggest The U.S. Healthcare Ecosystem: Payers, Providers, Producers , by Rob Burns. My friend Rob of the University of Pennsylvania’s Wharton School offers an exhaustive look into the commercial side of our complicated and confusing healthcare system. . You will be amazed and overwhelmed by the amount of material crammed into this volume.

Drugs 52

Drugs Hospitals 52

The Pharma Data

AUGUST 5, 2021

Alcohol consumption is a major risk factor for several cancers including head & neck (mouth, pharynx, larynx), oesophageal and bowel cancer – as well as the more widely known links to breast and liver cancer – according to a new study funded by World Cancer Research Fund (WCRF)(1), and published this week in Nature Communications. The study also found increased coffee consumption was associated with a lower risk of developing liver cancer and basal cell carcinoma of the skin.

DNA 52

DNA Research Disease 52

Drug Patent Watch

AUGUST 6, 2021

Annual Drug Patent Expirations for IMVEXXY Imvexxy is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Therapeuticsmd Inc drug IMVEXXY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Patent Watch

AUGUST 6, 2021

Annual Drug Patent Expirations for ARMONAIR+DIGIHALER Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent for Teva Pharm drug ARMONAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

AUGUST 6, 2021

Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are nineteen…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

AUGUST 6, 2021

Annual Drug Patent Expirations for NOURESS Nouress is a drug marketed by Baxter Hlthcare Corp and is included in one NDA. There are eleven patents protecting this drug. Drug patent…. The post New patent for Baxter Hlthcare drug NOURESS appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

AUGUST 5, 2021

This chart shows the drugs with the most patents in Colombia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Colombia? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Patent Watch

AUGUST 5, 2021

Annual Drug Patent Expirations for ORKAMBI Orkambi is a drug marketed by Vertex Pharms Inc and is included in two NDAs. It is available from one supplier. There are nineteen…. The post New patent for Vertex Pharms drug ORKAMBI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

AUGUST 5, 2021

Annual Drug Patent Expirations for GOCOVRI Gocovri is a drug marketed by Adamas Pharma and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent for Adamas Pharma drug GOCOVRI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

AUGUST 5, 2021

Upadacitinib (30 mg, once daily) monotherapy demonstrated significantly greater rates of skin clearance improvement and itch reduction compared to dupilumab (300 mg, every other week) monotherapy at 16 weeks[1] – Early, significant results were seen in upadacitinib-treated patients — including skin clearance improvements (EASI 75) at two weeks and itch reduction at one week — compared to dupilumab[1] – The safety profile of upadacitinib was consistent with previous atopi

Treatment 52

Treatment FDA Vaccine Disease 52

The Pharma Data

AUGUST 5, 2021

Group sales increase by 12.9 percent (Fx & portfolio adj.) to 10.854 billion euros – double-digit percentage growth (Fx & portfolio adj.) at all divisions / EBITDA before special items declines by 10.6 percent to 2.577 billion euros, burdened by currency effects of 153 million euros / Crop Science posts strong sales growth, earnings impacted by higher costs and currency effects / Pharmaceuticals reports significant recovery after COVID-19 effects in prior year / Consumer Health continues

Production 52

Production Pharmaceuticals Science Therapies 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

The Pharma Data

AUGUST 5, 2021

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite , a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility’s assets and leases in Gaithersburg, MD, from Kite. The transaction was announced on July 19, 2021. This press release features multimedia.

Therapies 52

Therapies Small Molecule Vaccine Science 52

The Pharma Data

AUGUST 5, 2021

today announced that it has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec. The divestiture is part of Bristol Myers Squibb’s ongoing evolution of its manufacturing network to support its product portfolio. Switzerland remains an important strategic location for the Company, and Bristol Myers Squibb expects to maintain a strong presence in the country.

Production 52

Production 52

Drug Patent Watch

AUGUST 4, 2021

This chart shows the pharmaceutical companies with the most patents in Finland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Finland? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Drug Patent Watch

AUGUST 4, 2021

Annual Drug Patent Expirations for LANSOPRAZOLE Lansoprazole is a drug marketed by Ajanta Pharma Ltd, Alkem Labs Ltd, Breckenridge, Dr Reddys Labs Ltd, Hetero Labs Ltd Iii, Inventia, Krka Tovarna…. The post New patent for Dexcel Pharma drug LANSOPRAZOLE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

AUGUST 4, 2021

Annual Drug Patent Expirations for NOXAFIL Noxafil is a drug marketed by Merck Sharp Dohme, Schering, and Msd Merck Co and, and is included in four NDAs. It is available…. The post New patent for Merck Sharp drug NOXAFIL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

AUGUST 4, 2021

Annual Drug Patent Expirations for TAZVERIK Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-two patents protecting this drug. This drug has…. The post New patent for Epizyme Inc drug TAZVERIK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. – Year-to-date revenue grew 11 percent – excluding revenue from COVID-19 antibodies – with strong sequential growth from first quarter to second quarter 2021, suggesting continued recovery from the COVID-19 pandemic in lin

Production 52

Production Marketing Research DNA 52

The Pharma Data

AUGUST 3, 2021

Breakthrough results in the treatment of a type of heart failure, which is extremely difficult to manage Strong progress in mental health pipeline Good business performance in all areas, despite ongoing impact of COVID-19. In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before.

Research 52

Research Treatment Clinical Trials Production 52

The Pharma Data

AUGUST 3, 2021

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a more than $200 million endowment to the Gilead Foundation to further the company’s vision of creating a healthier world for all people. The Gilead Foundation, established in 2005, builds on the company’s longstanding commitment to supporting underserved communities around the world. It aims to create impact in the community and society by encouraging a culture of giving, engaging in local communities and exploring innovative approaches

Science 52

Science International Disease 52

The Pharma Data

AUGUST 3, 2021

today announced financial results for the second quarter of 2021. Key results include: Total revenues increased 5% to $6.5 billion in comparison to the second quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

AUGUST 3, 2021

Positive Phase IIb results for eliapixant in patients with refractory chronic cough. Bayer today announced positive results from the Phase IIb clinical trial evaluating the efficacy and safety of its investigational orally administered, potent and selective P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough. The primary efficacy outcome was met showing a statistically significant improvement in 24-hour cough counts per hour (average hourly cough frequency

Clinical Trials 52

Clinical Trials Treatment Trials International 52

The Pharma Data

AUGUST 3, 2021

– New data from Phase 3 COV-BARRIER sub-study indicates one death prevented for every six baricitinib-treated patients on mechanical ventilation or ECMO compared to placebo – Data showed 46% risk reduction in mortality by Day 28 and 44% risk reduction in mortality by Day 60. announced today results from an additional cohort of 101 adult patients from the COV-BARRIER trial.

Hospitals 52

Hospitals FDA FDA Approval Licensing 52

Drug Patent Watch

AUGUST 3, 2021

Annual Drug Patent Expirations for STIOLTO+RESPIMAT Stiolto Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are fourteen…. The post New patent expiration for Boehringer Ingelheim drug STIOLTO RESPIMAT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

AUGUST 3, 2021

This chart shows the drugs with the most patents in Israel. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Israel? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

AUGUST 3, 2021

Annual Drug Patent Expirations for COMBIVENT+RESPIMAT Combivent Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are seven…. The post New patent expiration for Boehringer Ingelheim drug COMBIVENT RESPIMAT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52